(0.23%) 5 143.50 points
(0.19%) 38 514 points
(0.33%) 17 904 points
(-0.56%) $83.38
(1.82%) $1.958
(0.08%) $2 349.10
(0.25%) $27.61
(0.75%) $929.00
(-0.17%) $0.933
(-0.23%) $11.00
(-0.27%) $0.798
(1.15%) $92.93
3 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 6.24%
@ $25.39
发出时间: 15 Feb 2024 @ 04:49
回报率: -23.95%
上一信号: Feb 14 - 22:30
上一信号:
回报率: 3.63 %
Live Chart Being Loaded With Signals
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis...
Stats | |
---|---|
今日成交量 | 602 518 |
平均成交量 | 673 876 |
市值 | 1.45B |
EPS | $0 ( 2024-02-22 ) |
下一个收益日期 | ( $-0.190 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -18.93 |
ATR14 | $0.0250 (0.13%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-01 | Eastham Karin | Buy | 10 000 | Common Stock |
2024-04-01 | Eastham Karin | Sell | 10 000 | Common Stock |
2024-04-01 | Eastham Karin | Sell | 10 000 | Stock Option (right to buy) |
2024-03-15 | Chambers Rebecca | Buy | 4 318 | Common Stock |
2024-03-15 | Chambers Rebecca | Sell | 2 189 | Common Stock |
INSIDER POWER |
---|
32.58 |
Last 99 transactions |
Buy: 1 146 076 | Sell: 688 515 |
音量 相关性
Veracyte Inc 相关性 - 货币/商品
Veracyte Inc 财务报表
Annual | 2023 |
营收: | $361.05M |
毛利润: | $223.15M (61.81 %) |
EPS: | $-1.020 |
FY | 2023 |
营收: | $361.05M |
毛利润: | $223.15M (61.81 %) |
EPS: | $-1.020 |
FY | 2022 |
营收: | $296.54M |
毛利润: | $194.95M (65.74 %) |
EPS: | $-0.510 |
FY | 2021 |
营收: | $219.51M |
毛利润: | $145.11M (66.11 %) |
EPS: | $-1.419 |
Financial Reports:
No articles found.
Veracyte Inc
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。